US Endocrine Senior Manager, Access and Patient Marketing

ROLE SUMMARY The Endocrine team comprises 2 products, Ngenla and Genotropin. Ngenla is a once-weekly pediatric growth hormone deficiency (pGHD) therapy that launched in June 2023 and is poised to become the anchor product of the franchise. Genotropin was the first product approved to treat pGHD in 1987. Approximately 1 in 4,000 US children are affected by pGHD and can result in physical, emotional, and social burden for the patients and their families. Current therapies (including Genotropin) require patients to commit to daily injections, leaving patients tethered to a strict injection schedule, which can impact quality of life and lead to suboptimal adherence, which affects their growth trajectory.…